Latham & Watkins Advises on PepGen’s IPO

PepGen, Inc., a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, has announced the pricing of its initial public offering. The offering consists of 9,000,000 shares of common stock at an initial public offering price of US$12 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses payable by PepGen, are expected to be US$108 million. In addition, PepGen has granted the underwriters a 30-day option to purchase up to an additional 1,350,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. All of the shares of common stock are being offered by PepGen. The shares are expected to begin trading on the Nasdaq Global Select Market on May 6, 2022, under the symbol “PEPG.” The offering is expected to close on May 10, 2022, subject to the satisfaction of customary closing conditions.

Latham & Watkins LLP represents the underwriters in the offering with a capital markets team led by New York partners Nathan Ajiashvili and Alison Haggerty, with associates Milo LeDoux, Brian Yoon, and Alexandra Kustra.